Novotech, a full-service global contract research organization (CRO), has been honored with multiple awards at the 2024 Clinical Trials Arena Excellence Awards. These prestigious accolades recognize Novotech’s achievements in business development, innovation, and marketing, underscoring the company’s commitment to advancing clinical trials and delivering professional solutions to the biotechnology sector.
Dr. John Moller, CEO of Novotech, commented, “We are extremely grateful for this industry recognition, which reflects the dedication and hard work of our entire team. This honor highlights what we can achieve when we work together, and we will continue to build on this momentum.”
The Clinical Trials Arena Excellence Awards celebrate excellence and innovation within the pharmaceutical industry, recognizing organizations that drive progress and advancement. Novotech’s recognition highlights its proactive approach, cutting-edge technology, and strong global presence.
Key Highlights of Novotech’s Award-Winning Strategy:
- Business Expansion: Novotech has significantly broadened its scope through strategic acquisitions, including NCGS, EastHORN, and CBR International. These acquisitions strengthen Novotech’s operational capabilities and expand its service offerings, ensuring the company maintains local expertise in key biotechnology hubs. The launch of the Early Stage Strategic Delivery Unit (EP SDU) leverages the clinical advantages and regulatory efficiencies of Australia and New Zealand, enhancing trial support for biotechnology companies.
- Data-Driven Innovation: Novotech also won the Innovation Award for its continued application of advanced technologies such as artificial intelligence (AI) and big data analytics to streamline clinical trial design and execution. Collaborations with Medidata and ObvioHealth enhance the company’s ability to conduct virtual trials, optimize site selection, accelerate patient recruitment, and improve overall trial outcomes.
- Strategic Marketing Leadership: Under the leadership of Toyna Chin, Global Marketing Director, Novotech has revamped its brand strategy, solidifying its position as a global leader in the CRO space. A strategic, multi-faceted promotional campaign has significantly boosted Novotech’s brand awareness, particularly in the US and European markets. Toyna Chin shared, “We are honored to receive this award, which reflects the outstanding contributions of our marketing team. This achievement is a result of our collective passion, collaboration, and drive toward a common goal.”
About Novotech
Founded in 1997, Novotech is a full-service, specialized biotechnology contract research organization (CRO) focused on accelerating the development of innovative medicines and therapies across all stages.
Recognized for its industry excellence, Novotech has earned multiple accolades, including the Frost & Sullivan 2024 Global Biotech CRO Award, the 2024 Clinical Trials Arena Excellence Awards, and the 2024 Employer of Choice and Great Place to Work awards in the US. Novotech also holds the Asia-Pacific Contract Research Organization of the Year Award since 2006.
With over 5,000 clinical projects spanning Phase I to Phase IV trials, Novotech operates 34 offices globally and employs more than 3,000 professionals. The company is a trusted partner in drug development, regulatory services, and clinical trials.
